Insights from the Fedora team on antimicrobial resistance, the science of our pipeline, and the fight against drug-resistant infection.
Why the antibiotic innovation gap is so dangerous, and how Fedora's science — from tazobactam to nacubactam to FPI-2119 — is answering it.
Read more →Eight posters and two oral presentations showcase potent bactericidal activity against antibiotic-resistant infections.
Read more →Potent antibacterial activity against Gram-negative community and hospital-acquired infections, across eight posters and two presentations.
Read more →Fedora to present a full suite of preclinical findings on FPI-2119 at the ESCMID congress in Munich, Germany.
Read more →A novel PBP-targeting antibiotic demonstrates broad in-vitro activity, bactericidal effects, and low resistance selection.
Read more →Four posters at the inaugural IMARI conference summarize the mechanism, activity, and resistance profile of FPI-2119.
Read more →Fedora will unveil its first-in-class lead candidate at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation.
Read more →
